Filing Flows › Cytosorbents (CTSO) › Q2 2026
Cytosorbents (CTSO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Cytosorbents (CTSO) reported revenue of $9.6M for the second quarter 2026 (Q2 2026), +0.2% from a year earlier and +9% from the quarter before. Operating margin was -27.4%, net loss $4.4M (45.9% of revenue).
Cytosorbents, Q2 2026: revenue $9.6M (+0.2% year over year), operating margin -27.4%, net loss $4.4M, operating cash flow −$583K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.6M | +9% | +0.2% |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$4.4M | — | -327% |
| Operating cash flow | −$583K | — | — |
What changed
Revenue was $9.6M in Q2 2026, roughly flat year over year and up 9% from the previous quarter.
Gross margin was 73.2%, up 2.3 points from Q2 2025. Operating costs exceeded revenue by $2.6M, an operating margin of -27.4%. Operating expenses fell 7% while revenue was flat. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $4.4M, narrower than the previous quarter's $5.1M loss.
Operating cash flow was −$583K. Non-cash charges added back $360K of depreciation and amortization and $368K of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $14K exceeded it, leaving free cash flow of −$597K.
Questions
What was Cytosorbents' revenue in the second quarter 2026?
Cytosorbents (CTSO) reported revenue of $9.6M for the second quarter 2026 (Q2 2026), +0.2% from a year earlier and +9% from the quarter before.
Was Cytosorbents profitable in the second quarter 2026?
Operating loss was $2.6M (-27.4% of revenue) and net loss $4.4M.
Source: Cytosorbents 10-Q on SEC EDGAR.